Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
Patents for C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
12/2005
12/27/2005CA2189271C Novel erythromycin derivatives, method for their preparation and their use as drugs
12/22/2005WO2005121130A2 Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
12/22/2005WO2005121095A1 Pyridine analogs as c5a antagonists
12/22/2005WO2005121093A1 Lxr receptor modulators
12/22/2005WO2005121065A2 DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
12/22/2005WO2005113537A3 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
12/22/2005WO2005053610A3 Diamine and iminodiacetic acid hydroxamic acid derivatives
12/22/2005US20050282881 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/22/2005US20050282236 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
12/22/2005CA2569402A1 Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
12/22/2005CA2569395A1 Diamine .beta.2 adrenergic receptor agonists
12/22/2005CA2569111A1 Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
12/22/2005CA2568673A1 Pyridine analogs as c5a antagonists
12/22/2005CA2564642A1 Lxr receptor modulators
12/21/2005EP1607389A1 4-protected-amino-2-substituted-1,2,3,4-tetrahydroquinolines as intermediates for CETP inhibitors
12/21/2005EP1606263A1 Ring-substituted 8-aminoquinoline derivatives as antimalarial agents
12/21/2005EP1606262A1 Novel crystalline forms of aripiprazole
12/21/2005EP1432701B1 Heterocyclic compounds for use in the treatment of disorders of the urinary tract
12/21/2005EP1377567B1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
12/21/2005EP1363897B1 Antagonists of mcp-1 function and methods of use thereof
12/21/2005EP1362039B1 Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
12/21/2005CN1711252A 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
12/21/2005CN1711246A Resolution of mefloquine with o,o-di-p-aroyltartaric acid
12/21/2005CN1232508C Cyclization process step in making of quinolones and phenodiazine
12/20/2005US6977266 Pyridone derivatives having affinity for cannabinoid 2-type receptor
12/20/2005US6977255 8-Substituted 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-ones inhibitor of phosphoinositide (PI) 3- kinase, an enzyme that regulates platelet-adhesion (antithrombotic agent)
12/20/2005CA2302412C Aminoalkylphenol derivatives and related compounds
12/20/2005CA2092896C Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
12/15/2005WO2005118546A1 Novel crystalline forms of gatifloxacin
12/15/2005WO2005118538A2 Arylsulfonamides and uses as hydroxysteroid dehydrogenase
12/15/2005WO2005117837A1 Process for preparation of amorphous form of a drug
12/15/2005US20050277665 e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes
12/15/2005US20050277650 Process for preparing aripirazole hydrate
12/15/2005US20050277646 N-[4-({5-(4-fluorophenyl)-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}oxy)-1,3-benzothiazol-2-yl]acetamide; vanilloid (capsaicin) receptor antagonist/agonist; antiinflammatory, analgesic, antiarthritis, antirheumatic; diseases involving sensory nerve function
12/15/2005US20050277644 Pyridine analogs as C5a antagonists
12/15/2005US20050277632 2-Hydroxyethylamines 2-substituted by a hydroxy-N-heterocycle and N-substituted by an omega-phenyl-1,1-dimethylalkyl group: 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one; betamimetics
12/15/2005US20050277631 Vanilloid receptor ligands and their use in treatments
12/15/2005DE102004026026A1 New 2-(hetero)aryl-tetrahydroquinoline derivatives and 1,2,3,4-tetrahydro-1,5-naphthyridine derivatives are mitotic motor protein Eg5 inhibitors used as anticancer agents for treating carcinoma or leukemia
12/15/2005DE102004022925B3 Flotationsreagenz und deren Verwendung zur Flotation für sulfidische Erze Flotation reagent and its use for the flotation of sulfidic ores
12/15/2005CA2561858A1 Arylsulfonamides and uses related thereto
12/15/2005CA2560984A1 Process for preparation of amorphous form of a drug
12/14/2005EP1604665A1 C-kit kinase inhibitor
12/14/2005EP1603898A2 Chemical derivatives binding very specifically with g-quadruplex dna structures and use thereof as a specific anti-cancer agent
12/14/2005EP1603884A2 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
12/14/2005EP1603883A2 Quinoline-derived amide modulators of vanilloid vr1 receptor
12/14/2005EP1603882A2 Urea and thiourea derivatives
12/14/2005EP1603881A2 Substituted thiophenes with antibacterial activity
12/14/2005EP1603880A1 Quinolinone/benzoxazinone derivatives and uses thereof
12/14/2005EP1603858A2 Kcnq channel modulating compounds and their pharmaceutical use
12/14/2005EP1440052B1 Benzamide derivatives as antagonists of orexin receptors
12/14/2005EP1224165B1 Novel compounds
12/14/2005EP1121355B1 Quinoline derivatives and their use as antibacterial agents
12/14/2005CN1708489A 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
12/14/2005CN1231439C Novel hydronaphtalene compounds prepared by phodium catalyzed ring opening reaction in presence of phosphine ligand
12/13/2005US6974876 Method for preparing intermediates useful in synthesis of retroviral protease inhibitors
12/08/2005WO2005115992A1 Theramutein modulators
12/08/2005WO2005115972A1 Therapeutic compounds
12/08/2005WO2005115145A2 Quinone substituted quinazoline and quinoline kinase inhibitors
12/08/2005WO2002057256A9 Piperazinylcarbonylquinolines and -isoquinolines
12/08/2005US20050272931 Vanilloid receptor ligands and their use in treatments
12/08/2005US20050272823 improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines
12/08/2005US20050272801 Isoprenoid pathway inhibitors for stimulating cartilage growth
12/08/2005US20050272777 Vanilloid receptor ligands and their use in treatments
12/08/2005US20050272769 8-hydroxy-5-[(R)-1-hydroxy-2-(6-phenethylamino-hexylamino)ethyl]-1H-quinolin-2-one; pulmonary disease: asthma or chronic obstructive pulmonary disease, pre-term labor, a neurological disorder, a cardiac disorder, or inflammation; long duration of action
12/08/2005US20050272768 Process for preparation of amorphous form of a drug
12/08/2005US20050272745 Novel piperidine and piperazine derivatives
12/08/2005US20050272742 Process for making aripiprazole particles
12/08/2005DE19930557B4 Verfahren zur Herstellung von Hydraten von Ciprofloxacin und von Ciprofloxacin-Anhydrat enthaltenden pharmazeutischen Zusammensetzungen Process for the preparation of hydrates of ciprofloxacin and of ciprofloxacin containing pharmaceutical compositions anhydrate
12/08/2005DE102004017662B3 New 1-amino-tetrahydronaphthalene derivatives, useful for treatment of e.g. inflammation, bind with high selectivity to glucocorticoid receptors
12/08/2005CA2567813A1 Theramutein modulators
12/08/2005CA2565066A1 Therapeutic compounds
12/07/2005EP1601656A1 Tetrahydroquinoline derivatives useful as serine protease inhibitors
12/07/2005EP1601655A2 Method for producing optically active amines
12/07/2005EP1097138B1 Pharmaceutical compositions comprising 2-quinolones
12/07/2005CN1705730A Electroluminescent iridium compounds having red-orange or red emission and devices made with such compounds
12/07/2005CN1704404A Tricyclic protein kinase inhibitors
12/07/2005CN1704403A Nano rare earth m-hydroxy benzoic acid 8-hydroxyquinoline antibacterial agent and method for preparing same
12/07/2005CN1230418C Selective androgen receptor modulators and methods of use thereof
12/07/2005CN1230173C Preventives and remedies for complications of diabetes
12/06/2005US6972296 Antichoelsterol agents; cardiovascular disorders; antihistamines; multiple sclerosis; antihistamines
12/06/2005US6972295 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis
12/06/2005US6972288 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
12/06/2005CA2206787C 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same
12/06/2005CA2163115C N-substituted beta-aryl- and beta-heteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
12/06/2005CA2096528C Retroviral protease inhibitors
12/01/2005WO2005113551A1 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
12/01/2005WO2005113542A2 N-cyclic sulfonamido inhibitors of gamma secretase
12/01/2005WO2005113537A2 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
12/01/2005WO2005113509A1 Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
12/01/2005WO2005113508A1 Stable crystal of 4-oxoquinoline compound
12/01/2005WO2005113507A1 Substituted quinoline derivatives as mitotic kinesin inhibitors
12/01/2005WO2005113506A1 Compounds and compositions as ppar modulators
12/01/2005WO2005113152A1 Collector for sulfidic ores
12/01/2005WO2005060963A8 Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
12/01/2005WO2005060456A3 Method for treating adamts-5-associate disease
12/01/2005WO2004101544A8 Benzyl sulfonamide derivatives as androgen receptor antagonists
12/01/2005WO2004085401A8 1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
12/01/2005US20050267214 Containing a quinolinecarbonylalkyl group, e.g., N1-[3-[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl) amino]butanediamide
12/01/2005US20050267206 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
12/01/2005US20050267199 2-Amino- and 2-thio- substituted 1,3-diaminopropanes
1 ... 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 ... 277